Market Overview

My goal is to be on stage with my computer and let you
see my screen and make sure you know what buttons to
press, where you’re getting in & out, how to calculate
risk, your targets — all of those things.
It’s real-life trading. Make sure you sign up!
- Jerremy Newsome

MLV & Co. Initiates SciClone Pharmaceuticals At Buy


Analysts at MLV & Co. initiated coverage on SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) with a Buy rating.

The target price for SciClone Pharmaceuticals is set to $15.

SciClone Pharmaceuticals shares have gained 78.29 percent over the past 52 weeks, while the S&P 500 index has surged 7.17 percent in the same period.

SciClone Pharmaceuticals' shares fell 0.21 percent to close at $9.36 on Friday.

Latest Ratings for SCLN

Nov 2016Initiates Coverage OnBuy
Jun 2015Initiates Coverage onBuy
Nov 2014DowngradesBuyHold

View More Analyst Ratings for SCLN
View the Latest Analyst Ratings

Posted-In: MLV & Co.Initiation Analyst Ratings


Related Articles (SCLN)

View Comments and Join the Discussion!

Latest Ratings

View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

KeyBanc Initiates Babcock & Wilcox With Overweight

Bank of America Initiates Black Knight Financial With Neutral